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ABSTRACT 
Background: Acute care units (ACUs) with focused sickle cell disease (SCD) care have been 
shown to effectively address pain and limit hospitalizations compared to emergency departments 
(ED), the reason for differences in admission rates is understudied. Our aim was compare effects 
of usual care for adult SCD pain in ACU and ED on opioid doses and discharge pain ratings, 
hospital admission rates and lengths of stay. 
Methods: In a retrospective, comparative cohort, single academic tertiary center study, 148 
adults with sickle cell pain received care in the ED, ACU or both. From the medical records we 
documented opioid doses, unit discharge pain ratings, hospital admission rates, and lengths of 
stay. 
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Findings: Pain on admission to the ED averaged 8.7±1.5 and to the ACU averaged 8.0±1.6. The 
average pain on discharge from the ED was 6.4±3.0 and for the ACU was 4.5±2.5. 70% of the 
144 ED visits resulted in hospital admissions as compared to 37% of the 73 ACU visits. 
Admissions from the ED or ACU had similar inpatient lengths of stay. Significant differences 
between ED and ACU in first opioid dose and hourly opioid dose were noted. 
Conclusions: Applying guidelines for higher dosing of opioids for acute painful episodes in 
adults with SCD in ACU was associated with improved pain outcomes and decreased 
hospitalizations, compared to ED.  Adoption of this approach for SCD pain in ED may result in 
improved outcomes, including a decrease in hospital admissions. 
Keywords: pain, acute care unit, emergency department, sickle cell disease, opioid, hospital 
admission 
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 INTRODUCTION  
1.1 Background 
Sickle cell disease (SCD) is caused by a point mutation of the β-globin gene, causing a 
valine to replace glutamic acid at position 6. As a result, when sickle hemoglobin is 
deoxygenated, it is able to polymerize into stiff rod like fibers within the red blood cell, causing 
its shape to be distorted, and on light microscopy may have the appearance of a sickle.  In 
addition to the shape change, it causes the lysis of red cells, impairs blood flow, causing 
ischemia, and many other physiological changes, including the hallmark characteristic of the 
disease: pain.   
The majority of the estimated 100,000 people in the U.S. living with SCD experiencing 
severe acute pain episodes go to an emergency department (ED) for care[1-3]. Uncontrolled, 
severe pain is the most common reason for more than 225,000 ED visits annually, and is the 
leading cause for admission to the hospital for those with SCD[4-8]. In the U.S. alone, the annual 
combined ED and inpatient charges for SCD have been estimated to be $2.4 billion[9].  
In some hospitals patients are able to go to specialized acute care units (ACUs) for 
SCD[9]. Patients cared for in these ACUs have a much lower hospital admission rate than those 
cared for in an ED[10, 11]. However, the reason for the difference in admission rates between 
these two types of units has not been well explored.  
1.2 Goal of this Study 
We were not able to find any studies that quantified the opioid doses given in an ED 
compared to an ACU, which if different, may help explain the differences in admission rates, and 
could help establish new treatment guidelines for SCD. The aim of our study was to compare 
effects of usual care for SCD pain of adults in the ACU and the ED of the same hospital on 
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opioid doses, ACU and ED discharge pain ratings, hospital admission rates and lengths of stay. 
We hypothesized that opioid doses would be higher for patients receiving usual care in the ACU 
than in the ED and that pain ratings at discharge, hospital admission rates, and lengths of stay 
would be lower for patients receiving care in the ACU than the ED.   
2.0 METHODS 
2.1 Design 
We conducted a retrospective, paired (when available) comparative cohort study. We abstracted 
from the electronic medical record data for all pain-related visits to the ED and ACU by subjects 
with SCD during the 2 years of study participation. From this abstracted dataset, we then 
extracted data for only the first visit to the ED and the first visit to the ACU for each patient.  
The study protocol was approved by the (blinded) Institutional Review Board. 
2.2 Setting 
 The ED and ACU are both part of the Blinded Hospital and Health Sciences System. The 
ED is the hospital’s 24-hour Emergency epartment. The ACU is independent of the ED and 
managed by separate administrators. The ACU is located within the Sickle Cell Clinic of the 
Blinded Hospital, and established as an alternative to the ED but open 8 am to 5 pm, Monday 
through Friday, during the study period. Patients admitted to the ACU are those with 
uncomplicated pain crises who are unable to manage their pain at home. The ACU healthcare 
providers have expertise managing SCD pain crises. Since the ACU is located within the Sickle 
Cell Clinic, patients have ready access to their regular physicians with SCD expertise. Patients 
experiencing complicated pain crises (e.g., severe chest pain or headache, fever, crisis due to 
pregnancy, among others) are not admitted to the ACU and must be evaluated and treated in the 
ED. Patients who require pain crisis care after the hours of the ACU are admitted to the ED. 
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2.3 Sample 
The study subjects were patients who received their care at the (blinded) Sickle Cell 
Clinic. Subjects met the following criteria: 1) age 18 years or older, 2) diagnosis of SCD, 3) 
English speaking, 4) consented to participate in a SCD pain study, and 5) received care from the 
ED or ACU during the 2-years of their participation in the SCD pain study.  
The sample of 148 subjects was nearly two-thirds female, and the mean age of the sample 
was 35.1±11.9 years. Table 1 presents the demographic characteristics of the subjects. From 
Table 1, we observed that there were no significant demographic differences between subjects 
utilizing the ED only, ACU only, or both ED and ACU. 
2.4 Procedure  
Trained by the PhD prepared principal investigator (PI) and supervised by a PhD 
prepared project director, two reviewers, a research assistant and an expert research nurse, 
extracted data from the subjects’ electronic medical records. The abstracted data included the 
reason for the visit, presence of pain, medications administered, and pain intensity values (called 
pain hereafter) at admission and discharge, which the clinical staff obtained using a 0-10 verbal 
scale, with 0 as no pain and 10 as worst pain. Specifically, the medication data included the 
analgesic drugs, doses, and routes for the first and subsequent doses administered during ED and 
ACU visits. We also collected the ACU and ED admission and discharge times and disposition 
and the hospital admission and discharge dates. In 5 occasions (2 for ACU and 3 for ED), 
patients discharged home returned to ED on the same day or the next day. In all 5 occasions, the 
patient was admitted to hospital. These hospitalizations were attributed to the corresponding 
ACU or ED visit. 
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Inter-rater reliability of the data abstraction was assessed by a third reviewer, another 
PhD prepared nurse researcher who was also trained by the PI. The third reviewer completed 
independent extraction of the data for 10% of the 1,281 ED and ACU visits, which were 
randomly selected by the study statistician and were unknown to the first two reviewers. The 
study statistician calculated the inter-rater reliability of the data abstraction, which was 92%. At 
the time of the data abstraction, all three reviewers were blind to the study goals, but they were 
not blind to the setting of care since they were documenting data for all pain care the subject 
received during the pain study period.  
2.5 Analysis 
Data analysis was completed using statistical software R. Descriptive statistics (mean, 
standard deviation, count, and frequency) were obtained for key demographic variables and 
baseline measures. Fisher’s tests and ANOVA were used to compare demographics of patients 
visiting ED exclusively, ACU exclusively, and both. To compare patient outcomes between ED 
and ACU, we performed mixed-effect regression of patient outcomes using initial pain and 
setting as predictors. We used a subject-specific random effect term to account for the overlap of 
subjects between two study settings. The amount of missing data was minimal (<1%). For 
missing data processing, we utilized multiple imputation to generate multiple completed datasets, 
upon which inference was performed and then aggregated. 
We utilized two approaches to examine the dosage of opioids that subjects received. In 
our first approach, we converted all dosages into intravenous (IV) morphine sulfate equivalent 
(IVMSEQ) values, by equating a 1 mg hydromorphone dose with a 5 mg morphine dose. This 
conversion enables comparison of the dosages of subjects given different drugs. In our second 
approach, we compared the first and hourly opioid doses received by a subject against the 
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recommended dose levels for morphine and hydromorphone and classified the dosages into four 
levels: below standard 0.05mg/kg/2hr of morphine (<0.01 mg/kg/2hr for hydromorphone); 
standard dosing 0.05-0.1 mg/kg/2hr for morphine (0.01-0.015 mg/kg/2hr for 
hydromorphone)[12]; augmented 0.1-0.15 mg/kg/2hr of morphine (0.015-.0.025 mg/kg/2hr of 
hydromorphone)[13]; and enhanced >0.15 mg/kg/2hr of morphine (0.025 mg/kg/2hr of 
hydromorphone). For a subject receiving both morphine and hydromorphone, we classified their 
opioid dosage level based on the dominant opioid they received.  
3.0 RESULTS 
3.1 Pain at Admission and Discharge 
 Appearing in Table 2 are the statistics for pain scores at admission to, and discharge from 
the two study settings. The initial admission pain (called initial pain hereafter) for the ED visits 
averaged 8.7±1.5 and for the ACU visits averaged 8.0±1.6. The average pain on discharge from 
the ED was 6.4±3.0 whereas for the ACU the average pain on discharge was 4.5±2.5. Whereas 
the average initial pain for the ED was slightly (0.7 point) higher than the ACU; at discharge 
however, the gap grew to a 1.9-point difference. The plot of initial pain versus discharge pain for 
these two settings (Figure 1) clearly shows that given the same initial pain, an ED subject often 
had much higher pain at discharge than an ACU subject. 
The estimated coefficients in Table 3 show that both initial pain and setting were highly 
statistically significant (p<.001). Not surprisingly, a higher initial pain predicted a higher 
discharge pain. The contrast between the two settings confirmed what we observed in Figure 1 
with an ED subject having a discharge pain 1.34 points higher than an ACU subject on average 
given the same initial pain. 
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3.2 Hospital Admissions and Inpatient Length of Stay (LOS) 
 The subject’s pain at discharge determined whether a subject needed to be admitted to the 
hospital. In our study sample, subjects with discharge pain greater than 5 were admitted to the 
hospital 82% (82% in ED and 84% in ACU) of the time, whereas those with lower discharge 
pain were only admitted 25% (40% in ED and 13% in ACU) of the time. Among those admitted 
into the hospital after first going to ED, the LOS was 8.8±7.4 for patients with high discharge 
pain and 8.0±5.3 for those with low (<=5) discharge pain. For patients that went to ACU, the 
LOS was 5.7±2.8 and 10.3±6.2, respectively. 
The results of the hospital admission and LOS also appear in Table 2. About 70% of the 
144 ED visits resulted in the subjects being admitted to the hospital, whereas 37% of the 73 ACU 
visits resulted in the subjects being admitted to the hospital. Subjects who were admitted from 
the ED or ACU had similar average inpatient lengths of stay. More specifically, average LOS for 
an admitted ED subject was 8.7±7.1 days while that of an admitted ACU subject was 9.3±5.9 
days. We applied a mixed-effect regression model using ED or ACU initial pain and setting as 
predictors to examine the setting difference in hospital admission rates and LOS. The parameter 
estimates in Table 3 showed that controlling for initial pain, a subject going to ED had a 
significantly higher (odds ratio=exp(1.42)=4.1, p<.001) chance of being admitted to a hospital 
than a subject going to ACU. In contrast to the hospitalization rate, we did not find significant 
associations between the LOS (for those admitted to a hospital) and setting (p=.36).    
3.3 Medications 
Table 2 also shows the results of the comparisons of type of medications administered 
and opioid dosages in the ED and ACU. In the ED, 67% of the subjects were given morphine 
first, 28% received hydromorphone first, and the remaining 5% did not receive any opioids. For 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Opioid Doses for Sickle Cell Disease Pain  
10 
 
the ACU, 74% of the subjects were first given morphine and 26% of the subjects were first given 
hydromorphone. The statistics of hourly morphine and hydromorphone dosages (for those 
receiving each drug) showed that ACU subjects were given higher dosages.  
3.4 IVMSEQ Analysis 
The mean and standard deviation (SD) of first, total, and hourly dosage received for 
subjects during visits to ED and ACU appear in Table 2. We observed that ACU had higher 
values for all three dosage indicators.  
Applying a linear mixed effect model to the first dosage, we found that controlling for 
initial pain, an ACU subject received a significantly higher (2.52 mg IVMSEQ, p<.001, Table 3) 
first dose than an ED subject. For a subject with an initial pain of 8, a difference of 2.52 mg 
IVMSEQ corresponds to a 40% dosage difference. Somewhat surprisingly, the subject’s initial 
pain seemed to only have a minor effect on the first dosage: a 1-point increase in initial pain was 
associated with only a 0.30 mg IVMSEQ increase in first dosage (p=.14). 
We also analyzed the total IVMSEQ dosage given to subjects during their entire visit 
since dosages most likely would increase as the visit length increased. We also expected 
IVMSEQ dosages would be different in the two settings, given that ACU appeared to be more 
aggressive in medicating. Therefore, we examined the initial pain and setting effects and the 
rates at which the total IVMSEQ dosages increased with the visit length in each setting. The 
coefficient estimates in Table 3 confirm that in both settings, the total IVMSEQ dosage increased 
significantly with time (2.26 mg IVMSEQ/hr, p<.001 for ED and 5.19 mg IVMSEQ/hr, p=.002 
for ACU). Again, the initial pain was not strongly associated with the total dosage (1.04 mg 
IVMSEQ/1-point, p=.30). The ACU subject received a significantly higher IVMSEQ total 
dosage (10.68 mg higher for a visit of 5 hours, a typical visit length, p=.004). 
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A similar model was used to analyze the hourly dosage in the two settings. Initial pain 
was significantly associated with the hourly dosage (0.31 mg IVMSEQ/hr/1-point, p=.04). The 
ACU was significantly higher than ED in hourly dosage, too (1.75 mg IVMSEQ/hr, p<.001).  
3.5 Dosage Level Analysis 
 The dosage level statistics shown in Table 2 again confirm that in the ACU there was 
more aggressive prescribing of opioids, with a much lower percentage of subjects receiving a 
below standard dose, and much higher percentage of subjects receiving either augmented or 
enhanced levels of opioids, compared with ED. Furthermore, none of the subjects required 
naloxone. The regression outcomes in Table 3 show that the differences between ED and ACU 
first dosage levels and hourly dosage levels were highly significant (p=.004 and p<.001, 
respectively). 
4.0 DISCUSSION 
The findings of this retrospective usual care study of the opioid doses given to subjects with SCD 
experiencing acute pain episodes in the E  compared to the ACU are impressive. Controlling for 
the subjects’ pain scores at admission, those who were cared for in the ACU were treated with 
significantly higher first, hourly, and total IVMSEQ doses compared to the ED. Those subjects 
who were treated in the ACU were treated with doses of medication that were more consistent 
with published guidelines for the management of painful episodes in SCD[11, 13]. It should be 
pointed out that none of the subjects required naloxone reversal. The hospitalization rate and 
discharge pain were significantly lower in the ACU than the ED. Although some authors have 
reported that those admitted to the hospital from an ACU had a shorter LOS[11], we did not find 
the difference to be statistically significant in our study.  
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Recommendations for dosing of opioids in SCD for acute pain episodes have been 
published by several groups[13, 15]. There is, however, a lack of clinical data showing either the 
effectiveness, or lack of effectiveness, of these doses.  
Our findings are observational but show the difference in pain and admission between 
two settings, with one setting (ACU in this study) more consistently applying the guidelines for 
higher mg/kg doses of morphine or hydromorphone for management of acute pain episodes of 
SCD. We grouped patients into one of four mg/kg treatment groups (below standard, standard, 
augmented, and enhanced). This weight-based dosing allows for a more personalized medication 
approach, when treatments include hydrophilic drugs such as morphine or hydromorphone, than 
categorizing patients into those weighing less than 50kg or more. Using this approach, we found 
that in the ED 54% of patients received either a below standard or standard first dose, whereas in 
the ACU only 37% received either of these doses. Conversely, in the ED only 15% of patients 
received an augmented hourly dose and 24% were treated with an enhanced dose, whereas in the 
ACU, more than twice (32%) as many received an augmented dose and 34% were treated with 
an enhanced dose.  
Both settings used morphine as the first-choice drug, so drug selection is not the likely 
explanation for the larger IVMSEQ doses used in the ACU. Surprisingly though, the subject’s 
initial pain seemed to have only a minor effect on the first dose (a 1-point increase in the initial 
pain was associated with only a 0.30mg IVMSEQ increase of the first dose). In the ACU, where 
the staff were trained in treatment of SCD pain, after the response to the first dose was assessed, 
patients received more than twice as large hourly doses over time (5.19 IVMSEQ/hr) than in the 
ED (2.26 mg IVMSEQ/hr). Therefore, we conclude that the ACU clinicians were more 
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aggressive than ED clinicians in prescribing larger opioid doses, a safe practice since no patients 
required naloxone reversal. 
  Implementing more effective approaches for controlling acute pain episodes of SCD are 
urgently needed to improve patients’ quality of life and care, decrease the need for healthcare 
utilization including hospital admissions, and lower medical costs. In 1985, Grady Memorial 
Hospital in Atlanta opened a specialized, 24-hour unit to care for SCD patients who were having 
acute pain episodes that they could not control at home, instead of having to use its very busy 
ED[27]. Due to its dramatic success in decreasing hospital admission rates, similar units have 
been established throughout the world for adults as well as children with SCD. Although there is 
a wide variation in their operation, they appear to universally reduce admission rates to the 
hospital[10, 13, 28-30] and demonstrate substantial savings[11]. Some have shown a decrease in 
the inpatient length of stay as well[11]. There are several reasons suggested to explain the 
success of these specialized units caring only for those with SCD including having staff who 
choose to and enjoy working with SCD patients on a regular basis, and quicker administration of 
pain medication. Unfortunately, most people with SCD do not have access to these units, and it 
would be difficult to implement ACUs universally. However, this study reveals significant 
differences in the dosing of opioid therapy between the ACU and ED. If larger opioid doses were 
implemented in the ED for control of SCD pain, it is possible that it would help improve patient 
care, including a decrease in hospital admissions. 
There are limitations to our study. It is important to note that the ACU provided care for 
patients with uncomplicated pain crises, whereas the ED could have had patients with more 
complicated pain episodes, which may have contributed to the higher hospital admission rate of 
patients admitted from the ED. Because this study was a retrospective observational study with 
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medical record review, evidence generated is less generalizable than a prospective double-blind 
randomized controlled trial. Other limitations may have included confounding patient, provider, 
or environmental determiners that, at the time of patient care, were not known or measured. 
Also, medical record reviewers were not blinded to setting of care, which could have led to 
biasing of results[31, 32]. The high inter-rater reliability rate (92%) on 10% of visits randomly 
selected, however, provides evidence of minimal abstraction bias. 
5.0 CONCLUSIONS  
 Our analysis of practice-based electronic health record data generated important insights 
about management of acute pain episodes for adults with SCD. Applying guidelines for higher 
dosing of opioids for acute pain episodes of SCD in the acute care setting was associated with 
less pain and decreased hospitalization. Adoption of this approach for the treatment of sickle cell 
pain in the ED may result in improved patient care, including a decrease in hospital admissions. 
Although not every ED has the resources to have SCD specialists readily available for pain care, 
most all EDs have sufficient resources to systematically and carefully increase opioid doses to 
those that provide adequate pain control for adults with SCD and thereby reduce hospital 
admissions. A prospective randomized controlled trial of guideline-based dosing of opioids for 
acute pain episodes of SCD is warranted to test the generalizability of our observational findings 
to additional settings.  
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Table 1. Demographic Characteristics of Participants Receiving Care in the Emergency 
Department (ED), Acute Care Unit (ACU) or Both Settings (N=148) 
 
 Overall Both ED Only ACU Only p Value 
Gender      
Male 52 (35%) 22 (32%) 29 (39%) 1 (25%) .67 
Female 96 (65%) 47 (68%) 46 (61%) 3 (75%)  
SC Type      
Hb SS 110 (74%) 49 (71%) 59 (79%) 2 (50%)  
Hb SC 21 (14%) 10 (14%) 10 (13%) 1 (25%) .34 
Other (SB+, SBTh, …) 17 (12%) 10 (14%) 6 (8%) 1 (25%)  
Race/Ethnicity      
Race White 2 (1%) 2 (3%) 0 (0%) 0 (0%)  
Black 145 (98%) 66 (96%) 75 (100%) 4 (100%) .18 
Mixed 1 (1%) 1 (1%) 0 (0%) 0 (0%)  
Ethnicity Hispanic 5 (3%) 2 (3%) 3 (4%) 0 (0%) 1 
Non-Hispanic 143 (97%) 67 (97%) 72 (96%) 4 (100%)  
Age, mean (SD) 35.1 (11.9) 34.8 (11.7) 35.0 (12.2) 40.5 (11.0) .65 
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Table 2. Pain Ratings, Hospital Admission Rates, Length of Stay (LOS) and Medication by 
Emergency Department (ED) and Acute Care Unit (ACU) 
 
  ED (N=144) ACU (N=73) 
Pain Rating Initial Pain, mean (SD) 8.7 (1.5) 8.0 (1.6) 
 Discharge Pain, mean (SD) 6.4 (3.0) 4.5 (2.5) 
Hospitalization Admission, n (%) 101 (70%) 27 (37%) 
 LOS*, mean (SD) 8.7 (7.1) 9.3 (5.9) 
First Opioid Morphine, n (%) 97 (67%) 54 (74%) 
 Hydromorphone, n (%) 40 (28%) 19 (26%) 
 No Opioid, n (%) 7 (5%) 0 (0%) 
Morphine Dose Hourly, Mean (SD), mg/hr 2.8 (2.6) 4.0 (2.3) 
Hydromorphone Dose Hourly, Mean (SD), mg/hr 1.0 (0.8) 1.5 (1.0) 
Opioid Dose First Dose, Mean (SD), 
IVMSEQ 
6.8 (3.8) 9.2 (5.4) 
 Total, Mean (SD), IVMSEQ 19.5 (21.0) 33.6 (27.2) 
 Hourly, Mean (SD), 
IVMSEQ/hr 
3.8 (3.5) 5.3 (3.8) 
First Dose Below Standard, n (%) 27 (19%) 5 (7%) 
 Standard, n (%) 51 (35%) 22 (30%) 
 Augmented, n (%) 30 (21%) 22 (30%) 
 Enhanced, n (%) 36 (25%) 24 (33%) 
Hourly Dose Below Standard, n (%) 46 (32%) 9 (12%) 
 Standard, n (%) 42 (29%) 16 (22%) 
 Augmented, n (%) 21 (15%) 23 (32%) 
 Enhanced, n (%) 35 (24%) 25 (34%) 
*LOS statistics are average of admitted patients 
IVMSEQ = Intravenous morphine sulfate equivalent  
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Table 3. Regression Analysis of Patient Outcomes and Medication  
 
Outcome Predictor Estimate Std Error z value p value 
Discharge Pain Setting 
(ref=ACU) 
1.34 0.35 3.86 <.001 
 Initial Pain 0.59 0.13 4.67  <.001 
Hospitalization 
Rate 
Setting 
(ref=ACU) 
1.42 0.37 3.81 <.001 
 Initial Pain 0.22 0.12 1.87 .06 
LOS Setting 
(ref=ACU) 
-1.00 1.07 -0.94 .36 
 Initial Pain 0.49 0.40 1.24 .23 
First Opioid 
Dosage 
Setting 
(ref=ACU) 
-2.52 0.59 -4.28 <.001 
 Initial Pain 0.30 0.20 1.51 .14 
Total Dosage Setting 
(ref=ACU) 
-10.68 3.53 -3.03 .004 
 Initial Pain 1.04 1.00 1.04 .30 
 Visit Length 
(ED) 
2.26 0.59 3.80 <.001 
 Visit Length 
(ACU) 
5.19 1.57 3.31 .002 
Hourly Dosage Setting 
(ref=ACU) 
-1.75 0.38 -4.66 <.001 
 Initial Pain 0.31 0.15 2.05 .04 
First Dosage 
Category 
Setting 
(ref=ACU) 
-0.95 0.32 -2.92 .004 
 Initial Pain 0.11 0.11 1.03 .30 
Hourly Dosage 
Category 
Setting 
(ref=ACU) 
-1.34 0.34 -3.96 <.001 
 Initial Pain 0.24 0.11 2.11 .03 
 
ED = Emergency Department, ACU = Acute Care Unit 
Dosage Category = Below Standard, Standard, Augmented, Enhanced 
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Figure 1. Initial and Discharge Pain Ratings in Two Settings:  Emergency Department (ED) and 
Acute Care Unit (AC)    
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Figure 1. 
 
ED = Emergency Department 
AC = Acute Care Unit 
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